X

Drug Profile

Colchicine - Romeg Therapeutics

Alternative Names: Colchicine USP; GLOPERBA

Latest Information Update: 28 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ROMEG Therapeutics
Developer Scilex Holding
Class Anti-ischaemics; Antigouts; Antineoplastics; Colchicum alkaloids; Small molecules; Vascular disorder therapies
Mechanism of Action Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Gout

Most Recent Events

16 Jan 2025 Colchicine licensed to Scilex Holding worldwide
29 Aug 2024 Scilex Holding Company receives FDA approval from the FDA for supplemental NDA label of GLOPERBA
10 Jun 2024 GLOPERBA® Launched for Gout (Prevention, In adults) in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com